01 September 2003
Long term survival in a patient with malign pleuralmesothelioma after gemcitabine treatment
Ugur Coskun , Nazan Gunel , Yesim YildirimCase Rep Clin Pract Rev 2003; 4(2):92-93 :: ID: 429040
Abstract
Background: Malign pleural mesothelioma is a chemoresistant tumor. Despite of advancement in chemoterapeutic agent, its prognosis remains poor.Case Report: Gemcitabine can be used as first line therapy in malign mesothelioma with a responce rate of 7% to 30%. Second line agents in this tumor are ineffective. We present a malign pleural mesothelioma (MPM) case treated with gemcitabine as a second line agent. Conclusions: Long term survival is achived with gemcitabine threapy in MPM.
Keywords: Mesothelioma, Gemcitabine, Survival
638
In Press
Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.952443
Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.953173
Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.953192
Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.952818
Most Viewed Current Articles
07 Dec 2021 : Case report
22,364,578
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report 
174,245
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
119,744
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
64,648
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133